Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rilzabrutinib shows positive results in phase 2b for pemphigus

Publish date:: July 17, 2020

Key clinical point: A novel oral Bruton’s tyrosine kinase inhibitor showed good efficacy with a favorable safety profile in pemphigus.

Major finding: Sixty percent of pemphigus patients achieved control of disease activity after 4 weeks on rilzabrutinib, an investigational oral reversible Bruton’s tyrosine kinase inhibitor.

Study details: This was a phase 2b, 24-week, open-label trial in 15 patients with pemphigus.

Disclosures: The presenter reported serving as a consultant to Principia Biopharma, sponsor of the BELIEVE-PV trial, and has received institutional research grants from numerous pharmaceutical companies.

Citation:

FROM AAD 20

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Medical Dermatology

New lupus classification criteria perform well in children, young adults,

Phone outreach intervention feasible to reduce SLE readmissions,

Age, smoking among leading cancer risk factors for SLE patients,

Cachexia affects more than half of lupus patients,

Ixekizumab deemed effective for pityriasis rubra pilaris,